Yini Ongayilindela Ezimweni Zokuqeda Ukukhipha Isisu NgokweDokotela
I-RU486 (igama elithi brand Mifeprex) liye lasetshenziswa kabanzi, ngokuphumelelayo futhi lisetshenziswa ngokuphepha eFrance, eSweden naseBrithani iminyaka eminingi. Iphilisi lokukhipha isisu RU486 liphinde livunyelwe i-FDA ukuthi lisetshenziswe e-US. Iphilisi lokukhipha isisu (elibhekwe njengesiyisisu sokukhipha isisu) kumele linikezwe ochwepheshe bezempilo.
Ukuze ube nesisu sokukhipha isisu, kuzodingeka uvakashele umhlinzeki wezempilo wakho kathathu.
Ingxenye yokuqala yokukhipha isisu kuthatha iphilisi yokukhipha isisu RU486. Uma-ke, uma kunesidingo, i-RU486 kumele ilandelwe imithi yesibili, i-misoprostol, ukuqeda ngokuphelele ukukhulelwa.
Iyokuqala I-RU486 Ukuqokwa
Phakathi nalesi sihambeli, umhlinzeki wakho wezempilo kufanele kuqala aqaphele ukuthi ukhulelwe (ngokusebenzisa ukuhlolwa kokukhulelwa kanye / noma nokuhlolwa kwe-pelvic). Uma ukhulelwe, udokotela wakho angabe esethi usuku lokukhulelwa ngokusebenzisa i-sonogram (ngoba lokhu akuyona i-FDA-egunyaziwe, abanye abahlinzeki bangakhetha ukungenzi i-sonogram).
Khona-ke uzonikezwa amaphilisi amathathu (200 mg ngamunye) weMifeprex (RU-486) okufanele athathwe ngokushesha ngomlomo. Leli dose le-mifepristone lizokwenza ukuthi iqanda elikhukhunziwe lingakwazi ukuhlala lihambisana nombono wesisu.
Uzobe uhlela ukuqokwa kwakho okulandelayo ukuze kwenzeke izinsuku ezimbili kamuva.
Ukuqokwa kwesiBili
Phakathi nalolu hambo (okumelwe kube ngamahora angu-48 ngemuva kokuthi uthathe i-mifepristone), udokotela wakho uzokwenza ukuhlolwa ukuze abone ukuthi ukukhulelwa sekuphelile.
Uma kungenjalo, uzonikezwa umuthi wesibili, i-misoprostol, ngesimo samaphilisi amabili okufanele athathwe ngomlomo noma njengesidakamizwa se-vaginal suppository. Lo muthi kufanele uthathwe ehhovisi likadokotela futhi kufanele wenze ukuthi ukukhulelwa kuphele noma kuphi kusukela emahoreni ayisithupha kuya kwesonto elilodwa.
I-misoprostol izobangela ukuhlukunyezwa kwe-uterine, ngakho-ke ungase uzwe ukuchotshozwa nokugaya.
Udokotela wakho angase anikeze imithi ebuhlungu futhi akunikeze izinkomba uma kwenzeka isimo esiphuthumayo.
Ukuqokwa Kwokugcina
Kufanele ulandele ukuvakashela kudokotela wakho amasonto amabili emva kokuthatha i-misoprostol. Ngalesi sikhathi, udokotela wakho uzoqinisekisa ukuthi ukukhulelwa sekuphelile futhi kuqinisekisiwe ukuthi azikho ezinye izinkinga (njenge-hemorrhaging or infection). Uma kunqunywa ukuthi usakhulelwe, kuzophakanyiswa ukuthi uhlele inqubo yokuhlinza ukuqeda ukukhulelwa. Ngokombiko we-Mifeprex, "Iziguli ezinokukhulelwa okuqhubekayo kulokhu kuhambela zinengozi yokugula okungumntwana okubangelwa ukwelashwa. Ukususwa kokuhlinzwa kunconywa ukuphatha ukuhluleka kokukhipha isisu ngokwezempilo. "
Okuningi mayelana nePilisi yokukhipha isisu
Lapho kuthathwa yedwa, iphilisi lokukhipha isisu RU486 libangela ukukhipha isisu ngokuphelele mayelana namaphesenti angu-64 kuya ku-85% wesikhathi. Uma i-misoprostol inikezwa amahora angu-48 kamuva, ukuphumelelwa kokukhipha isisu kukhula kube ngamaphesenti angu-92 kuya ku-98%.
Ukukhipha isisu imiphumela yemiphumela ye-pill kungabandakanya ukugaya, ukuhlanza, ukuhlanza nokuhuda, nokuphuma kwamanzi okungapheli izinsuku eziyisishiyagalombili kuya kwezingu-10.
Iphilisi yokukhipha isisu RU486 kuphela i-FDA-evunyelwe owesifazane onamaviki ayisikhombisa akhulelwe (okulingana namaviki amahlanu kusukela ekukhulelwe) noma kuze kube yizinsuku ezingu-49 emva kokuphela kwesikhathi sokuya esikhathini.
Nakuba abanye abahlinzeki bezempilo bazobe besasebenzisa le ndlela kubantu besifazane abangaphezu kwamasonto ayisikhombisa abakhulelwe, sebenzisa ngalesi sikhathi kucatshangelwe-ilebula (okusho, hhayi i-FDA evunyelwe).
Naphezu kwenkolelo evamile, kubalulekile ukuqaphela ukuthi i-American Psychological Association ithole ukuthi abukho ubufakazi bokuthi isisu esisodwa singabangela izinkinga zempilo yengqondo .
Imithombo:
I-FDA. Ilebuli ye-Mifeprex . Ifinyelele ngo-5/12/08.
Spitz, IM, Bardin, CW, Benton, L. & Robbins, A. (1998). Ukuqeda ukukhulelwa kokuqala nge mifepristone ne-misoprostol e-United States. I-New England Journal of Medicine, i-338 (18) , i-1241-47. Kufinyelelwe ngokubhalisa kwangasese 5/12/08